ARNI for advanced lung cancer with high blood pressure
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if a heart failure drug called ARNI can help people with advanced lung cancer who also have high blood pressure. It aims to see if the drug improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced lung cancer (stage 3 or 4).
- You were diagnosed with high blood pressure before your lung cancer.
- You are at least 18 but under 80 years old.
- You are able to take care of yourself (ECOG score 0 or 1).
- Your organs (kidneys, liver) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a medication called ARNi works for people with high blood pressure in the United Arab Emirates. It may help if you are newly diagnosed or already taking one blood pressure pill.
This trial studies whether a heart medicine called ARNI (sacubitril-valsartan) is safe and works well for people who have a durable LVAD and moderate-to-severe heart pumping weakness. It may help improve symptoms and outcomes, while carefully checking side effects in this higher-risk group.
This trial tests a combination of three heart failure drugs (ARNI, SGLT2i, MRA) to see if they improve symptoms and outcomes in people with a type of heart failure where the heart pumps normally but doesn't relax properly (HFpEF).
This trial compares a newer heart failure medicine (ARNI) to an older one (ACE inhibitor) in children with a condition called dilated cardiomyopathy, where the heart is enlarged and weak. The goal is to see which medicine works better to help the heart pump more strongly.
This trial uses a special belt (EIT) to see how two different blood pressure medicines affect the balance of air and blood flow in the lungs of people on breathing machines in the ICU.
This Phase 3 trial tests ARINA-1 to slow or prevent worsening lung transplant scarring in the breathing tubes (bronchiolitis obliterans). It may help people who are showing early decline in lung function but are not yet at advanced disease.
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.